ImmunityBio, Inc. (IBRX)

Market Cap	8.15B +238.1%
Revenue (ttm)	165.79M +192.9%
Net Income	-992.36M
EPS	-0.99
Shares Out	1.06B
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,653,240
Open	7.79
Previous Close	7.92
Day's Range	7.54 - 7.83
52-Week Range	1.95 - 12.43
Beta	0.13
Analysts	Strong Buy
Price Target	12.75 (+65.8%)
Earnings Date	Aug 4, 2026

About IBRX

ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient’s immune system and deliver durable protection against cancer and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company’s platform has generated first-in-human therapeutic agents that are planned to be studied in clinical trials in liquid and so...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2014
• Employees: 691
• Stock Exchange: NASDAQ
• Ticker Symbol: IBRX
• Website: https://immunitybio.com

Financial Performance

In 2025, ImmunityBio's revenue was $113.29 million, an increase of 668.31% compared to the previous year's $14.75 million. Losses were -$351.40 million, -15.03% less than in 2024.

Analyst Summary

According to 4 analysts, the average rating for IBRX stock is "Strong Buy." The 12-month stock price target is $12.75, which is an increase of 65.80% from the latest price.

Price Target

$12.75

(65.80% upside)

Analyst Consensus: Strong Buy

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Aug 18, 2026

Data Sources Report a data error